RA CAPITAL MANAGEMENT, L.P. purchased $2.6M of ARTV (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. purchased 264,586 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at an average of $9.76 ($9.55–$9.96, $2.58M total) across 3 trades over 2026-07-21 to 2026-07-23.

Original reporting
SEC EDGAR · RA CAPITAL MANAGEMENT, L.P.
Published Jul 24, 2026, 1:22 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 24, 2026, 1:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Bullish
medium confidence
Mentioned
$ARTV
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVBullishLow
01

Why it matters

Traders may use the disclosed accumulation as a sentiment input, but there is no accompanying operational update (earnings, trial results, approvals, or guidance).

02

Market read

A $2.58M open-market purchase by a large insider-holder is newly disclosed, offering a modest sentiment signal for ARTV.

03

What to watch

No 10b5-1 plan is stated, but the filing does not clarify intent, tax considerations, or whether the purchases were pre-planned through other vehicles.

Relevance 7/10Novelty 5/10Timing: after-hours SEC Form 4 filed 2026-07-23 for trades dated 2026-07-21 to 2026-07-23

Background

The article is an SEC Form 4 insider transaction disclosure for Artiva Biotherapeutics, Inc. (ARTV).

Company-level read

Ticker impact

$ARTVBullishMedium confidence
Context

RA Capital Management, a director and 10% owner, bought 264,586 shares of Artiva Biotherapeutics in open-market trades totaling about $2.58M.

Expected impact

Likely limited near-term impact; could modestly support sentiment if traders treat it as a signal, but it is not a fundamental catalyst.

Evidence & confidence

Form 4 provides a fresh, time-stamped transaction (2026-07-21 to 2026-07-23) with a meaningful dollar value, yet the filing does not include new company fundamentals or guidance.

Market effects

Minimal; single-company biotech insider purchase without clinical or regulatory updates.

None indicated.

None indicated.

Counterpoint

Indirect holdings and multi-trade execution can reflect portfolio rebalancing rather than a new view on near-term fundamentals.

Key entities

  • Artiva Biotherapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • RA Capital Management, L.P.

    Director and 10% owner who reported an open-market purchase via indirect holdings.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.